Positron Corporation Retains FDA Consulting Firm in Preparation for 510K New Device Application

Niagara Falls, NY – February 17, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging device systems and clinical services company, is pleased to announce today that the Company has retained Medical Device Academy ”MDA”) as its consultant for the Company’s new PET/CT device 510K submission with the Food and Drug Administration (“FDA”). 

Positron will be applying for new device approval to market and sell its PET/CT device in the United States. The Company plans to file its 510K application within 60 days and anticipates it will receive approval within 100 days from initial filing date. 

Adel Abdullah, President of Positron stated: “The seasoned team at MDA come highly recommended for their expertise, analysis and assessment of the processes required for our new application to be successfully cleared by the FDA.  During the past several months we have been preparing our database to accept & present all relevant information and documentation for our 510K application. Hiring a skilled specialist such as MDA is key and the next step for Positron’s business to offer a state-of-the-art PET/CT device delivering the best images for cardiac patients and our future expected oncology customers.”